Top Page
Immutep Ltd
(Sydney:IMM)
Immutep Ltd (IMM) vs. iShares MSCI Australia ETF (EWA)
Immutep Ltd Business Overview & Revenue Model
Immutep Ltd Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.04M | 5.04M | 3.84M | 3.51M | 170.37K | 3.86M |
| Gross Profit | -56.37M | -56.37M | -37.70M | 1.44M | -1.89M | 1.79M |
| EBITDA | -62.88M | -62.88M | -44.54M | -42.88M | -31.87M | -20.72M |
| Net Income | -61.43M | -61.43M | -42.72M | -39.90M | -32.21M | -29.90M |
Balance Sheet | ||||||
| Total Assets | 156.98M | 156.98M | 201.58M | 147.45M | 102.17M | 82.03M |
| Cash, Cash Equivalents and Short-Term Investments | 129.69M | 129.69M | 181.88M | 123.42M | 80.00M | 60.13M |
| Total Debt | 1.63M | 1.63M | 1.59M | 1.23M | 1.73M | 2.82M |
| Total Liabilities | 13.35M | 13.35M | 12.06M | 10.98M | 8.09M | 8.76M |
| Stockholders Equity | 143.64M | 143.64M | 189.52M | 136.47M | 94.08M | 73.27M |
Cash Flow | ||||||
| Free Cash Flow | -62.10M | -62.10M | -35.75M | -35.93M | -30.25M | -17.66M |
| Operating Cash Flow | -62.05M | -62.05M | -34.82M | -35.88M | -30.23M | -17.64M |
| Investing Cash Flow | -38.53M | -38.53M | -21.02M | -31.00K | -22.91K | -15.60K |
| Financing Cash Flow | -525.12K | -525.12K | 95.18M | 76.04M | 50.33M | 52.68M |
Immutep Ltd Technical Analysis
Immutep Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | AU$541.41M | ― | -27.89% | ― | ― | 67.26% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | AU$294.19M | -20.59 | -83.97% | ― | 1271.12% | 36.87% | |
41 Neutral | $375.34M | ― | -35.86% | ― | ― | -19.21% | |
41 Neutral | AU$97.88M | ― | -42.68% | ― | ― | 63.46% | |
41 Neutral | $96.17M | ― | -83.09% | ― | ― | 55.94% | |
40 Underperform | AU$106.68M | -13.09 | -47.98% | ― | 700.00% | 26.88% |
Immutep Ltd Corporate Events
Immutep Limited has received a €2,588,954 (~ A$4,567,769) R&D tax incentive payment from the French Government under the Crédit d’Impôt Recherche scheme. This funding will support the global clinical development of eftilagimod alfa and IMP761, enhancing Immutep’s operations and potentially strengthening its position in the biotechnology industry.
The most recent analyst rating on (AU:IMM) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
Immutep Limited has announced its 2025 Annual General Meeting (AGM) scheduled for November 27, 2025, in Sydney, with provisions for a live webcast for those unable to attend in person. The AGM will address the company’s financial statements and include a resolution on the adoption of the Remuneration Report, which is advisory and non-binding, reflecting the company’s commitment to transparency and shareholder engagement.
The most recent analyst rating on (AU:IMM) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
Immutep Limited has released its corporate governance statement for the financial year ending 30 June 2025, which is available on their website. The statement, approved by the board, outlines the company’s adherence to the ASX Corporate Governance Council’s principles and recommendations, highlighting its commitment to transparency and accountability in its operations. This disclosure is crucial for stakeholders as it ensures compliance with governance standards, potentially impacting the company’s reputation and investor confidence.
The most recent analyst rating on (AU:IMM) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
Immutep Ltd has released its annual report for the year ending June 30, 2025, detailing its financial performance and strategic developments. The report highlights the company’s ongoing commitment to advancing its immunotherapy pipeline, which could significantly impact its market position and offer potential benefits to stakeholders in the biotechnology sector.
The most recent analyst rating on (AU:IMM) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
Immutep Limited has announced promising results from its INSIGHT-003 trial, presented at the ESMO Congress 2025, showcasing a novel combination of eftilagimod alfa (efti) with KEYTRUDA and chemotherapy. This combination has demonstrated strong objective response rates and disease control rates in first-line non-small cell lung cancer (1L NSCLC) patients across all PD-L1 expression levels, particularly benefiting those with low and no PD-L1 expression. The trial results suggest that efti could significantly alter the treatment landscape for 1L NSCLC, providing a new standard of care and addressing the high unmet need in patients with PD-L1 expression under 50%.
The most recent analyst rating on (AU:IMM) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
Immutep Limited announced positive results from its EFTISARC-NEO Phase II trial, which evaluated the novel combination of eftilagimod alfa (efti) with radiotherapy and KEYTRUDA® in treating resectable soft tissue sarcoma (STS). The trial met its primary endpoint, achieving a 51.5% tumor hyalinization/fibrosis rate, significantly surpassing the historical 15% rate from standard radiotherapy alone. This outcome suggests potential improvements in overall and recurrence-free survival for STS patients, addressing a critical unmet medical need. The findings, presented at the ESMO Congress 2025, highlight the promising efficacy and safety profile of efti, potentially paving the way for new therapeutic options in STS treatment.
The most recent analyst rating on (AU:IMM) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
Immutep Limited has successfully completed the FDA’s Project Optimus requirements, confirming 30 mg as the optimal biological dose for its immunotherapy candidate efti, which is significant for its oncology pipeline and future Biological License Applications. This development is strategically important for Immutep’s ongoing and future clinical trials, including the Phase III TACTI-004 trial for non-small cell lung cancer, positioning the company to advance its novel immunotherapy to market and address global cancer patient needs.
The most recent analyst rating on (AU:IMM) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
Immutep Limited has announced a significant milestone in its TACTI-004 (KEYNOTE-F91) Phase III trial for treating advanced non-small cell lung cancer (NSCLC). The trial, which combines eftilagimod alfa with KEYTRUDA and chemotherapy, has enrolled over 170 patients, surpassing the number needed for futility analysis. With over 100 clinical sites activated across 24 countries, the trial is on track for a futility analysis in early 2026. This development could potentially transform the treatment landscape for NSCLC, a major cancer type with high unmet medical needs, by enhancing response rates and improving efficacy regardless of PD-L1 expression.
The most recent analyst rating on (AU:IMM) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
Immutep Ltd announced a change in the director’s interest, where Mr. Pete Meyers converted 388,889 performance rights into fully paid ordinary shares. This change reflects the director’s compensation strategy, where he receives part of his fees in performance rights, aligning his interests with those of the shareholders.
The most recent analyst rating on (AU:IMM) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
Immutep Ltd has announced a change in the interest of its director, Dr. Frederic Triebel, involving the conversion of 900,000 performance rights into fully paid ordinary shares. This adjustment, which was previously approved by shareholders, reflects the company’s ongoing commitment to aligning executive incentives with shareholder interests, potentially impacting its market perception and stakeholder confidence.
The most recent analyst rating on (AU:IMM) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
Immutep Ltd announced a change in the director’s interest, with Mr. Marc Voigt acquiring 1,200,000 fully paid ordinary shares through the vesting and exercise of performance rights. This change reflects the company’s ongoing commitment to aligning executive interests with shareholder value, potentially impacting investor confidence and market perception positively.
The most recent analyst rating on (AU:IMM) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
Immutep Ltd has announced the issuance of 4,055,555 fully paid ordinary shares, which will be quoted on the Australian Securities Exchange (ASX) starting October 1, 2025. This move is part of the company’s strategy to enhance its capital structure and potentially strengthen its market position, offering stakeholders an opportunity to invest in its growth and development.
The most recent analyst rating on (AU:IMM) stock is a Buy with a A$1.20 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
Immutep Limited has announced a research collaboration with the George Washington University Cancer Center to initiate a Phase II trial evaluating eftilagimod alfa (efti) as a neoadjuvant therapy for early-stage HR+/HER2-negative breast cancer. The trial will explore efti’s potential to activate a broad anti-cancer immune response, potentially leading to high pathologic complete response rates and improved disease-free survival. This collaboration allows Immutep to expand its clinical pipeline cost-effectively and further positions efti as a promising immunotherapy in both metastatic and neoadjuvant cancer settings.
The most recent analyst rating on (AU:IMM) stock is a Buy with a A$1.20 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
Immutep Limited announced that data from its EFTISARC-NEO Phase II trial will be presented at the Connective Tissue Oncology Society (CTOS) 2025 Annual Meeting. This trial is the first to evaluate eftilagimod alpha in a neoadjuvant setting combined with radiotherapy and pembrolizumab for soft tissue sarcoma, an orphan disease with significant unmet medical needs. The trial, conducted in Poland and funded by the Polish government, could have implications for the treatment of soft tissue sarcoma, potentially improving outcomes in a field with poor prognosis.
The most recent analyst rating on (AU:IMM) stock is a Buy with a A$0.46 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
Immutep Limited reported a significant increase in its loss after tax for the financial year ending June 30, 2025, primarily due to a $19.9 million rise in research and development and intellectual property expenses, largely attributed to clinical trial costs. Despite a rise in other income and interest income, the company’s net tangible asset backing per ordinary security decreased, and no dividends were declared, indicating financial challenges amidst ongoing investments in its core research activities.
The most recent analyst rating on (AU:IMM) stock is a Buy with a A$0.98 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.